Literature DB >> 12123469

The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro.

R Chess-Williams1, C R Chapple, T Yamanishi, K Yasuda, D J Sellers.   

Abstract

1 The objective was to determine the role of muscarinic receptor subtypes in mediating contraction of the human detrusor smooth muscle in vitro. 2 Contractile responses of human detrusor muscle strips to carbachol were obtained in the absence and presence of a range of muscarinic antagonists (pirenzepine, methoctramine, 4-diphenylacetoxy-N-methyl piperidine methiodide (4-DAMP), tropicamide, oxybutynin and tolterodine). Affinity estimates (pKB values) were calculated for the antagonists and correlated with values at the cloned muscarinic receptor subtypes quoted in the literature. 3 Pirenzepine, methoctramine and tropicamide drugs that have high affinities at M1, M2 and M4-receptors, respectively, all had low affinities on the human detrusor (pKB values of 6.8, 6.9 and 6.5, respectively), whilst the M3-selective antagonist 4-DAMP had a high affinity (9.5). Schild plots for all four antagonists had slopes of unity indicating an action at a single receptor. Oxybutynin and tolterodine also acted as competitive antagonists with affinity estimates of 7.6 and 8.1, respectively. 4 When the antagonist affinities obtained on the bladder were plotted against the values published for these antagonists at the cloned muscarinic receptor subtypes, the best correlations were obtained for the m3- and m5-muscarinic receptor subtypes. 5 These data suggest that direct contractile responses of the human detrusor muscle to muscarinic receptor stimulation in vitro are mediated solely via the M3-muscarinic receptor subtype with no contribution from the major M2-receptor population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12123469     DOI: 10.1046/j.1365-2680.2001.00231.x

Source DB:  PubMed          Journal:  J Auton Pharmacol        ISSN: 0144-1795


  42 in total

Review 1.  Muscarinic receptors: what we know.

Authors:  Harriette M Scarpero; Roger R Dmochowski
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 3.092

2.  [New pharmacological treatment concepts for overactive bladder].

Authors:  M C Michel
Journal:  Urologe A       Date:  2003-04-25       Impact factor: 0.639

Review 3.  [The ice water test and bladder cooling reflex. Physiology, pathophysiology and clinical importance].

Authors:  T Hüsch; T Neuerburg; A Reitz; A Haferkamp
Journal:  Urologe A       Date:  2016-04       Impact factor: 0.639

Review 4.  Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

5.  Management of overactive bladder with transdermal oxybutynin.

Authors:  Jonathan S Starkman; Roger R Dmochowski
Journal:  Rev Urol       Date:  2006

6.  Anti-muscarinic drugs increase rectal compliance and exacerbate constipation in chronic spinal cord injury : Anti-muscarinic drug effect on neurogenic bowel.

Authors:  Abhilash Paily; Guiseppe Preziosi; Prateesh Trivedi; Anton Emmanuel
Journal:  Spinal Cord       Date:  2019-02-25       Impact factor: 2.772

7.  Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue.

Authors:  Melinda Wuest; Birgit Eichhorn; Manfred Braeter; Gerhard Strugala; Martin C Michel; Ursula Ravens
Journal:  Pflugers Arch       Date:  2007-12-21       Impact factor: 3.657

8.  Age-dependent contribution of Rho kinase in carbachol-induced contraction of human detrusor smooth muscle in vitro.

Authors:  Timo Kirschstein; Chris Protzel; Katrin Porath; Tina Sellmann; Rüdiger Köhling; Oliver W Hakenberg
Journal:  Acta Pharmacol Sin       Date:  2013-10-14       Impact factor: 6.150

Review 9.  The clinical pharmacokinetics of darifenacin.

Authors:  Andrej Skerjanec
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 10.  Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.

Authors:  G G Kay; U Ebinger
Journal:  Int J Clin Pract       Date:  2008-08-11       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.